A Phase 3 interventional study of Cemdisiran and Eculizumab in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Regeneron Pharmaceuticals. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-08.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal — none open to participants now, none under way, none of them phase 3. eculizumab · Hemoglobinuria, Paroxysmal.
Among the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal, this one is the 18th largest by enrollment, is the only one that started in 2022, is one of 14 in phase 3, and was the 15th registered.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.
Browse Hemoglobinuria, Paroxysmal studies →None of the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal is open now. The open studies under Hemoglobinuria, Paroxysmal, anywhere →
eculizumab: first FDA approval 2007 (SOLIRIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2022.
This study's enrollment of 3 is below the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Median enrollment 37 across the 18 interventional studies. Of the 18 that completed or were terminated, 9 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 18 have an industry lead sponsor. The 8 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals: 3 open now, 3 under way, 2 of them phase 3. Of 6 finished, 5 (83%) have results posted.
Among the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals, this one is one of 2 that started in 2022, is one of 5 in phase 3, and was the 5th registered.
Regeneron Pharmaceuticals’s Hemoglobinuria, Paroxysmal studies by the year they started, since 2019.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Regeneron Pharmaceuticals’s 10 in Hemoglobinuria, Paroxysmal:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is:
To evaluate the effect of pozelimab and cemdisiran combination therapy on hemolysis, as assessed by lactate dehydrogenase (LDH), after 36 weeks of treatment, in patients with PNH who switch from eculizumab or ravulizumab therapy versus patients who continue their eculizumab or ravulizumab therapy
The secondary objectives of the study are to:
Evaluate the effect of pozelimab and cemdisiran combination treatment versus anti-C5 standard-of-care treatment (eculizumab or ravulizumab) on the following:
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol-defined Inclusion/ Exclusion Criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Randomized 1:1
Drug: Cemdisiran · Drug: Eculizumab · Drug: Pozelimab · Drug: Ravulizumab
Randomized 1:1
Drug: Eculizumab · Drug: Ravulizumab
Administered per protocol
Also known as: ALN-CC5
Administered per protocol
Also known as: Soliris
Administered per protocol
Also known as: REGN3918
Administered per protocol
Also known as: ALXN1210, Ultomiris
Percent Change in Lactate Dehydrogenase (LDH) From Baseline to Week 36
Time frame: From baseline to week 36
Percentage of Participants With Transfusion Avoidance After Day 1 Through Week 36
Participants who do not receive a red blood cell (RBC) transfusion as per protocol algorithm based on post baseline hemoglobin values
Time frame: Day 1 through week 36
Percentage of Participants With Transfusion Avoidance From Week 4 Through Week 36
Participants who do not receive an RBC transfusion as per protocol algorithm based on post baseline hemoglobin values
Time frame: Week 4 through week 36
Percentage of Participants With Breakthrough Hemolysis After Day 1 Through Week 36
Participants with an increase in LDH with concomitant signs or symptoms associated with hemolysis as described in the protocol
Time frame: Day 1 through week 36
Percentage of Participants With Breakthrough Hemolysis From Week 4 Through Week 36
Participants with an increase in LDH with concomitant signs or symptoms associated with hemolysis as described in the protocol
Time frame: Week 4 (day 29) through week 36
Percentage of Participants With Hemoglobin Stabilization After Day 1 Through Week 36
Participants who do not receive an RBC transfusion and have no decrease in hemoglobin level as defined in the protocol
Time frame: Day 1 through week 36
Percentage of Participants With Hemoglobin Stabilization From Week 4 Through Week 36
Participants who do not receive an RBC transfusion and have no decrease in hemoglobin level as defined in the protocol
Time frame: Week 4 (day 29) through week 36
Percentage of Participants With Adequate Control of LDH From Week 8 Through Week 36
Percentage of participants with adequate control of LDH as defined in the protocol
Time frame: Week 8 (day 57) through week 36
Percentage of Participants With Adequate Control of LDH After Day 1 Though Week 36
Percentage of participants with adequate control of LDH as defined in the protocol
Time frame: Day 1 through week 36
Percentage of Participants Who Maintained Adequate Control of Hemolysis From Week 8 Through Week 36
Percentage of participants with adequate control of LDH as defined in the protocol
Time frame: Week 8 through week 36
Percentage of Participants Who Maintained Adequate Control of Hemolysis After Day 1 Through Week 36
Percentage of participants with adequate control of LDH as defined in the protocol
Time frame: Day 1 through week 36
Percentage of Participants With Normalization of LDH From Week 8 Through Week 36
Percentage of participants with normalization of LDH as defined in the protocol
Time frame: Week 8 (day 57) through week 36
Percentage of Participants With Normalization of LDH After Day 1 Through Week 36
Percentage of participants with normalization of LDH as defined in the protocol
Time frame: Day 1 through week 36
Change in Fatigue as Measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale From Baseline to Week 36
The FACIT-Fatigue is a 13 item, self-administered clinical outcome assessment (COA) assessing an individual's level of fatigue during their usual daily activities over the past week. This questionnaire is part of the FACIT measurement system, a compilation of questions measuring health related quality of life (QoL) in patients with cancer and other chronic illnesses. The FACIT-Fatigue assesses the level of fatigue using a Likert scale ranging from 0 (not at all) to 4 (very much). Scores range from 0 to 52, with higher scores indicating greater fatigue.
Time frame: From baseline to week 36
Change in Physical Function (PF) Score on the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 Items (EORTC-QLQ-C30) From Baseline to Week 36
EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including global health status/quality of life, functional Scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4-point scale, with 1 as "not at all" and 4 as "very much."
Time frame: From baseline to week 36
Change in Global Health Status (GHS)/QoL Scale Score on the EORTC-QLQ-C30 From Baseline to Week 36
EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including global health status/quality of life, functional Scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea and vomiting, and pain), and 7 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, sleep and financial difficulties). Participants rate items on a 4-point scale, with 1 as "not at all" and 4 as "very much."
Time frame: From baseline to week 36
Rate of RBCs Transfused Per Protocol Algorithm After Day 1 Through Week 36
Per protocol algorithm
Time frame: Day 1 through week 36
Rate of RBCs Transfused Per Protocol Algorithm From Week 4 Through Week 36
Per protocol algorithm
Time frame: Week 4 through week 36
Number of Units of RBCs Transfused Per Protocol Algorithm After Day 1 Through Week 36
Per protocol algorithm
Time frame: Day 1 through week 36
Number of Units of RBCs Transfused Per Protocol Algorithm From Week 4 Through Week 36
Per protocol algorithm
Time frame: Week 4 through week 36
Change in Hemoglobin Levels From Baseline to Week 36
Per protocol algorithm
Time frame: From baseline to week 36
Incidence of Treatment Emergent Serious Adverse Events (SAEs)
Treatment period and safety follow up period
Time frame: Up to week 29
Incidence of Treatment-emergent Adverse Events (TEAEs) of Special Interest
Treatment period and safety follow up period
Time frame: Up to week 29
Incidence of TEAEs Leading to Treatment Discontinuation
Treatment period and safety follow up period
Time frame: Up to week 29
Change in Total CH50 From Baseline to Week 36
Time frame: From baseline to week 36
Percent Change in Total CH50 From Baseline to Week 36
Time frame: From baseline to week 36
Concentration of Total C5 in Plasma Through Week 62
Treatment period and safety follow up period
Time frame: Through week 62
Concentrations of Total Pozelimab in Serum Through Week 62
Treatment period and safety follow up period
Time frame: Through week 62
Concentrations of Total Cemdisiran in Plasma Through Week 32
Treatment period
Time frame: Through week 32
Concentrations of Total Eculizumab in Serum Through Week 40
Treatment period
Time frame: Through week 40
Concentrations of Total Ravulizumab in Plasma Through Week 44
Treatment period
Time frame: Through week 44
Incidence of Treatment Emergent Anti-drug Antibodies (ADAs) to Pozelimab Through Week 62
Treatment period and safety follow up period
Time frame: Through week 62
Incidence of Treatment Emergent ADAs to Cemdisiran Through Week 62
Treatment period and safety follow up period
Time frame: Through week 62
| Milestone | Pozelimab and Cemdisiran | Anti-C5 Standard-of-care |
|---|---|---|
| Started | 2 | 1 |
| Completed | 0 | 0 |
| Not completed | 2 | 1 |
| Withdrew: Sponsor request | 2 | 1 |
No measurements were reported for this outcome.
Participants who do not receive a red blood cell (RBC) transfusion as per protocol algorithm based on post baseline hemoglobin values
No measurements were reported for this outcome.
Participants who do not receive an RBC transfusion as per protocol algorithm based on post baseline hemoglobin values
No measurements were reported for this outcome.
Participants with an increase in LDH with concomitant signs or symptoms associated with hemolysis as described in the protocol
No measurements were reported for this outcome.
Participants with an increase in LDH with concomitant signs or symptoms associated with hemolysis as described in the protocol
No measurements were reported for this outcome.
Participants who do not receive an RBC transfusion and have no decrease in hemoglobin level as defined in the protocol
No measurements were reported for this outcome.
Participants who do not receive an RBC transfusion and have no decrease in hemoglobin level as defined in the protocol
No measurements were reported for this outcome.
Percentage of participants with adequate control of LDH as defined in the protocol
No measurements were reported for this outcome.
Percentage of participants with adequate control of LDH as defined in the protocol
No measurements were reported for this outcome.
Percentage of participants with adequate control of LDH as defined in the protocol
No measurements were reported for this outcome.
Percentage of participants with adequate control of LDH as defined in the protocol
No measurements were reported for this outcome.
Percentage of participants with normalization of LDH as defined in the protocol
No measurements were reported for this outcome.
Percentage of participants with normalization of LDH as defined in the protocol
No measurements were reported for this outcome.
The FACIT-Fatigue is a 13 item, self-administered clinical outcome assessment (COA) assessing an individual's level of fatigue during their usual daily activities over the past week. This questionnaire is part of the FACIT measurement system, a compilation of questions measuring health related quality of life (QoL) in patients with cancer and other chronic illnesses. The FACIT-Fatigue assesses the level of fatigue using a Likert scale ranging from 0 (not at all) to 4 (very much). Scores range from 0 to 52, with higher scores indicating greater fatigue.
No measurements were reported for this outcome.
EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including global health status/quality of life, functional Scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4-point scale, with 1 as "not at all" and 4 as "very much."
No measurements were reported for this outcome.
EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including global health status/quality of life, functional Scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea and vomiting, and pain), and 7 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, sleep and financial difficulties). Participants rate items on a 4-point scale, with 1 as "not at all" and 4 as "very much."
No measurements were reported for this outcome.
Per protocol algorithm
No measurements were reported for this outcome.
Per protocol algorithm
No measurements were reported for this outcome.
Per protocol algorithm
No measurements were reported for this outcome.
Per protocol algorithm
No measurements were reported for this outcome.
Per protocol algorithm
No measurements were reported for this outcome.
Treatment period and safety follow up period
| Events | Pozelimab and Cemdisiran | Anti-C5 Standard-of-care |
|---|---|---|
| Incidence of Treatment Emergent Serious Adverse Events (SAEs) | 0 | 0 |
Treatment period and safety follow up period
| Events | Pozelimab and Cemdisiran | Anti-C5 Standard-of-care |
|---|---|---|
| Incidence of Treatment-emergent Adverse Events (TEAEs) of Special Interest | 1 | 0 |
Treatment period and safety follow up period
| Events | Pozelimab and Cemdisiran | Anti-C5 Standard-of-care |
|---|---|---|
| Incidence of TEAEs Leading to Treatment Discontinuation | 0 | 0 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Treatment period and safety follow up period
No measurements were reported for this outcome.
Treatment period and safety follow up period
No measurements were reported for this outcome.
Treatment period
No measurements were reported for this outcome.
Treatment period
No measurements were reported for this outcome.
Treatment period
No measurements were reported for this outcome.
Treatment period and safety follow up period
No measurements were reported for this outcome.
Treatment period and safety follow up period
No measurements were reported for this outcome.
Collected over From first dose to week 29. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pozelimab and Cemdisiran | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Anti-C5 Standard-of-care | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Event | Pozelimab and Cemdisiran | Anti-C5 Standard-of-care |
|---|---|---|
| Alanine aminotransferase increasedInvestigations | 0/2 | 1/1 |
| EczemaSkin and subcutaneous tissue disorders | 0/2 | 1/1 |
| Injection site rashGeneral disorders | 1/2 | 0/1 |
| Blood glucose increasedInvestigations | 1/2 | 0/1 |
| Age, Categorical(Participants) | Pozelimab and Cemdisiran | Anti-C5 Standard-of-care | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 1 | 3 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Pozelimab and Cemdisiran | Anti-C5 Standard-of-care | Total |
|---|---|---|---|
| Female | 1 | 0 | 1 |
| Male | 1 | 1 | 2 |
| Ethnicity (NIH/OMB)(Participants) | Pozelimab and Cemdisiran | Anti-C5 Standard-of-care | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 2 | 1 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Pozelimab and Cemdisiran | Anti-C5 Standard-of-care | Total |
|---|---|---|---|
| White | 1 | 0 | 1 |
| Black or African American | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Other | 0 | 0 | 0 |
| Unknown | 0 | 0 | 0 |
| Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
Ran from Oct 2022 to primary completion in Jul 2023, 9 months.
Results were first posted in Sep 2024, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Eculizumab · Ravulizumab